PCI Biotech Holding ASA logo

PCIB - PCI Biotech Holding ASA Share Price

NOK48.7 -0.1  -0.1%

Last Trade - 3:25pm

Sector
Healthcare
Size
Small Cap
Market Cap £154.0m
Enterprise Value £132.2m
Revenue £753k
Position in Universe 671st / 1782
Bullish
Bearish
Unlock PCIB Revenue
Momentum
Relative Strength (%)
1m -31.6%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -44.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
7.30 10.5 10.5 10.3 9.59 9.39 64.0 30.0 +5.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, PCI Biotech Holding ASA revenues decreased 21% to NOK1.9M. Net income totaled NOK4.4M vs. loss of NOK22.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income reflects Financial income increase from NOK659K to NOK20.7M (income), Financial Expenses - other decrease of 95% to NOK281K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PCIB Revenue Unlock PCIB Revenue

Net Income

PCIB Net Income Unlock PCIB Revenue

Normalised EPS

PCIB Normalised EPS Unlock PCIB Revenue

PE Ratio Range

PCIB PE Ratio Range Unlock PCIB Revenue

Dividend Yield Range

PCIB Dividend Yield Range Unlock PCIB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PCIB EPS Forecasts Unlock PCIB Revenue
Profile Summary

PCI Biotech Holding ASA is a Norway-based company engaged in the biotechnology sector. Its activities are focused on the commercialization of a patented photochemical drug delivery technology for use in the localized cancer treatment. The Company’s products are based on the Photochemical Internalization (PCI) technology for light-directed drug delivery, used to enhance the effect of drugs by targeted illumination of the diseased areas of the body. It focuses primarily on the drug candidate Amphinex, developed for treatment of head and neck cancer and bile duct cancer, as well as on the development of PCI for vaccination. As of December 31, 2011, it had a wholly owned subsidiary PCI Biotech AS and an affiliate PCIO Biotech Utibu, located in Iceland.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated March 19, 2007
Public Since June 18, 2008
No. of Shareholders: n/a
No. of Employees: 12
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Oslo Stock Exchange
Shares in Issue 37,265,890
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PCIB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PCIB
Upcoming Events for PCIB
Frequently Asked Questions for PCI Biotech Holding ASA
What is the PCI Biotech Holding ASA share price?

As of 3:25pm, shares in PCI Biotech Holding ASA are trading at NOK48.7, giving the company a market capitalisation of £154.0m. This share price information is delayed by 15 minutes.

How has the PCI Biotech Holding ASA share price performed this year?

Shares in PCI Biotech Holding ASA are currently trading at NOK48.7 and the price has moved by 91.93% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the PCI Biotech Holding ASA price has moved by 99.58% over the past year.

What are the analyst and broker recommendations for PCI Biotech Holding ASA?

Of the analysts with advisory recommendations for PCI Biotech Holding ASA, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for PCI Biotech Holding ASA is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will PCI Biotech Holding ASA next release its financial results?

PCI Biotech Holding ASA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the PCI Biotech Holding ASA dividend yield?

PCI Biotech Holding ASA does not currently pay a dividend.

Does PCI Biotech Holding ASA pay a dividend?

PCI Biotech Holding ASA does not currently pay a dividend.

When does PCI Biotech Holding ASA next pay dividends?

PCI Biotech Holding ASA does not currently pay a dividend.

How do I buy PCI Biotech Holding ASA shares?

To buy shares in PCI Biotech Holding ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of PCI Biotech Holding ASA?

Shares in PCI Biotech Holding ASA are currently trading at NOK48.7, giving the company a market capitalisation of £154.0m.

Where are PCI Biotech Holding ASA shares listed? Where are PCI Biotech Holding ASA shares listed?

Here are the trading details for PCI Biotech Holding ASA:

Country of listing: Norway
Exchange: OSL
Ticker Symbol: PCIB
What kind of share is PCI Biotech Holding ASA?

Based on an overall assessment of its quality, value and momentum, PCI Biotech Holding ASA is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a PCI Biotech Holding ASA share price forecast 2020?

Shares in PCI Biotech Holding ASA are currently priced at NOK48.7. At that level they are trading at 68.21% discount to the analyst consensus target price of 0.00.

Analysts covering PCI Biotech Holding ASA currently have a consensus Earnings Per Share (EPS) forecast of -1.3 for the next financial year.

How can I tell whether the PCI Biotech Holding ASA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PCI Biotech Holding ASA. Over the past six months, the relative strength of its shares against the market has been -0.34%. At the current price of NOK48.7, shares in PCI Biotech Holding ASA are trading at -10.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the PCI Biotech Holding ASA PE Ratio?

We were not able to find PE ratio data for PCI Biotech Holding ASA.

Who are the key directors of PCI Biotech Holding ASA?

PCI Biotech Holding ASA's management team is headed by:

Per Walday - CEO
Anders Hogset - CSO
Ronny Skuggedal - CFO
Hans Bohn - CHM
Christina Herder - DRC
Lars Viksmoen - DRC
Hans Olivecrona - OTH
Andrew Hughes - DRC
Hilde Furberg - DRC
Who are the major shareholders of PCI Biotech Holding ASA?

Here are the top five shareholders of PCI Biotech Holding ASA based on the size of their shareholding:

Erik Must AS Corporation
Percentage owned: 10.09% (3.76m shares)
Aasen (Kjetil Myrlid) Individual Investor
Percentage owned: 7.73% (2.88m shares)
MP Pensjon Pension Fund
Percentage owned: 6.06% (2.26m shares)
Radiumhospitalets Forskningsstiftelse Corporation
Percentage owned: 3.44% (1.28m shares)
Nordnet AB Corporation
Percentage owned: 2.77% (1.03m shares)
Similar to PCIB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.